4-氯-6-(三氟甲氧基)喹啉-3-羧酸乙酯 | 207231-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-(三氟甲氧基)喹啉-3-羧酸乙酯
• 英文名称: ethyl 4-chloro-6-(trifluoromethoxy)quinoline-3-carboxylate
• CAS: 207231-23-0
• 化学式: C₁₃H₉ClF₃NO₃
• 分子量: 319.668
• InChiKey: MCYOAKSELHWBGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-氯-6-(三氟甲氧基)喹啉-3-羧酸乙酯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、275.79 kPa 条件下， 生成
  参考文献：
  名称：

  高亲和力中央苯并二氮杂receptor受体配体：一系列新的吡唑并[4,3-c]喹啉-3-酮的合成与构效关系研究。

  摘要：

  制备了一系列在喹啉和N2-苯环上带有适当取代基的2-芳基（杂芳基）-2,5-二氢吡唑并[4,3-c]喹啉-3-（3H）-酮，并进行了测试。中央苯并二氮杂receptor受体配体。结构亲和关系研究的结果与先前提出的药效团模型完全吻合，此外，定量结构活性分析为高苯并二氮杂receptor受体亲和力的主要分子决定因素提供了更重要的见解。还确定并初步讨论了一些活性配体的内在活性。

  DOI：

  10.1016/s0968-0896(97)10039-6
• 作为产物：
  描述：

  对三氟甲氧基苯胺 在 三氯氧磷 作用下， 以 various solvent(s) 为溶剂， 反应 49.34h， 生成 4-氯-6-(三氟甲氧基)喹啉-3-羧酸乙酯
  参考文献：
  名称：

  高亲和力中央苯并二氮杂receptor受体配体：一系列新的吡唑并[4,3-c]喹啉-3-酮的合成与构效关系研究。

  摘要：

  制备了一系列在喹啉和N2-苯环上带有适当取代基的2-芳基（杂芳基）-2,5-二氢吡唑并[4,3-c]喹啉-3-（3H）-酮，并进行了测试。中央苯并二氮杂receptor受体配体。结构亲和关系研究的结果与先前提出的药效团模型完全吻合，此外，定量结构活性分析为高苯并二氮杂receptor受体亲和力的主要分子决定因素提供了更重要的见解。还确定并初步讨论了一些活性配体的内在活性。

  DOI：

  10.1016/s0968-0896(97)10039-6

文献信息

• [EN] PAPD5 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PAPD5 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2020219729A1

  公开（公告）日：2020-10-29

  The present application provides compounds that are PAPD5 inhibitors and are useful in treating a variety of conditions such as cancer, telomere diseases, and aging-related and other degenerative disorders.

  本申请提供了一些PAPD5抑制剂化合物，可用于治疗各种疾病，如癌症、端粒疾病以及与衰老和其他退行性疾病相关的情况。
• [EN] 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS<br/>[FR] DERIVES PYRIMIDINYLE 2,4-BISUSBTITUES UTILES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：AMGEN INC

  公开号：WO2003018021A1

  公开（公告）日：2003-03-06

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

  该发明涵盖了化合物、类似物、前药及其药物学上可接受的盐、药物组合物、用途以及预防和治疗癌症的方法。
• Substituted pyrimidinyl derivatives and methods of use
  申请人：——

  公开号：US20040063705A1

  公开（公告）日：2004-04-01

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

  本发明涵盖化合物、类似物、前药及其药学上可接受的盐、制药组合物、用途和预防和治疗癌症的方法。
• High affinity central benzodiazepine receptor ligands. Part 2: quantitative structure–activity relationships and comparative molecular field analysis of pyrazolo[4,3- c ]quinolin-3-ones
  作者：L. Savini、L. Chiasserini、C. Pellerano、G. Biggio、E. Maciocco、M. Serra、N. Cinone、A. Carrieri、C. Altomare、A. Carotti

  DOI：10.1016/s0968-0896(00)00262-5

  日期：2001.2

  A large series of 2-aryl(heteroaryl)-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones (PQ, 106 compounds), carrying appropriate substituents at the quinoline and N-2-phenyl rings, were designed, prepared and tested as central benzodiazepine receptor ligands. Compounds with an affinity significantly higher than the parent compound CGS-8216 were obtained, the most active ligand showing a pIC(50) = 10.35. Hansch and comparative molecular field analyses gave coherent results suggesting the main structural requirements of high receptor binding affinity. The possible formation of a three-centred hydrogen bond (HB) at the HB donor site H-2, as a key interaction for high receptor binding affinity, was assessed by the calculation and comparison of the molecular electrostatic potentials of a series of selected ligands. (C) 2001 Elsevier Science Ltd. All rights reserved.
• High affinity central benzodiazepine receptor ligands. Part 3: insights into the pharmacophore and pattern recognition study of intrinsic activities of pyrazolo[4,3- c ]quinolin-3-ones
  作者：Andrea Carotti、Cosimo Altomare、Luisa Savini、Luisa Chiasserini、Cesare Pellerano、Maria P. Mascia、Elisabetta Maciocco、Fabio Busonero、Manuel Mameli、Giovanni Biggio、Enrico Sanna

  DOI：10.1016/s0968-0896(03)00527-3

  日期：2003.11

  Novel 2-phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3-(3H)-ones (PQs) endowed with high affinity for central benzodiazepine receptor (BzR) were synthesized. In particular, 9-fluoro-2-(2-fluorophenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one (22) showed binding affinity in the subnanomolar concentration range and proved to be in vitro a potent antagonist. This finding allowed the nature of the hydrogen bonding receptor site H-2 to be established, as located between the N-1 nitrogen of the PQ nucleus and the ortho position of the N-2-aryl group. [S-35]tert-Butylbicyclophosphorothionate ([S-35]TBPS) binding assays and electrophysiological measurements of the effects on GABA-evoked Cl- currents at recombinant human alpha(1)beta(2)gamma(2L) GABA(A) receptors, expressed in Xenopus laevis oocytes, were used to assess the intrinsic activities of a large series of PQs. With the aim of extracting discriminant information and distinguishing BzR ligands with different profiles of efficacy, 51 PQ derivatives, including full and partial agonists, antagonists, and inverse agonists, were analyzed in a multidimensional chemical descriptor space, defined by the lipophilicity parameter CLOG P and 3-D molecular WHIM descriptors, by means of principal component analysis, k-nearest neighbors (k-NN) method, and linear discriminant analysis (LDA). The classification methods were applied to subsets of pairs of efficacy classes, and lipophilicity and 3-D size descriptors were detected as the discriminant variables by a stepwise linear discriminant analysis. LDA proved to be superior to k-NN, especially in classifying PQ ligands (60-84% of success in prediction ability) into categories of efficacies which were contiguous and quite overlapped in the hyperspace of variables. (C) 2003 Elsevier Ltd. All rights reserved.